Celgene's most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $96.00 short call and a strike $101.00 long call offers a potential 14.68% return on risk over the next 12 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $96.00 by expiration. The full premium credit of $0.64 would be kept by the premium seller. The risk of $4.36 would be incurred if the stock rose above the $101.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Celgene is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.
The RSI indicator is at 67 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks
Mon, 08 Sep 2014 13:10:15 GMT
Celgene's Revlimid Impresses in Phase III NDMM Study
Fri, 05 Sep 2014 19:45:07 GMT
3 Biotech picks: Gilead, Biogen & Celgene
Fri, 05 Sep 2014 16:54:00 GMT
Celgene: Good Data But What About the Patent Challenges?
Thu, 04 Sep 2014 15:01:00 GMT
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
Thu, 04 Sep 2014 11:30:00 GMT
Business Wire – Celgene Corporation today announced that data from FIRST —an open-label phase III randomized study of continuous REVLIMID in combination with dexamethasone in patients newly diagnosed with multiple myeloma who are not candidates for stem cell transplant—have been published in the Sept.
Related Posts
Also on Market Tamer…
Follow Us on Facebook